Navigation Links
Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo

and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

CONTACT: Media Contacts: Gwen Fisher, +1-484-865-5160, or Gerald Burr
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Managing Preanalytical Processes for Patient Safety
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
6. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
7. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
11. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
Post Your Comments:
(Date:7/31/2015)... 2015  In today,s ever-changing marketplace, call centers must ... increasingly connected, and increasingly impatient with slow service. The ... channels and tools is driving call centers to explore ... According to research by benchmarking firm, Best Practices, ... in a call center study realize the impact of ...
(Date:7/31/2015)... The Physician-Patient Alliance for Health & ... 2015, "Surviving Your Hospital Stay: Physician-Patient Alliance for ... A sentence was omitted from the ... "PPAHS is a member of the National Coalition to ... on the National Coalition to Promote Continuous Monitoring of ...
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... to be held on Wednesday, August 6, 2008 at 8:00 ... ... 5 Isolagen(TM), Inc. (Amex:,ILE) announced today positive top-line efficacy and safety ... the,Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles.,Each study, conducted ...
... WHIPPANY, N.J., Aug. 5 Nexgen Spine, a ... treatment of,degenerative disc disease, announced today that it ... Lumbar Artificial Disc in the European,Union., "We ... has,received CE mark approval," said Alastair Clemow, Ph.D., ...
Cached Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... see if they could reach a consensus on the steps that need to be ... the group reached 90 percent consensus on a series of steps that each surgeon ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... negligence is now available online at ( http://www.lawline.com/cle/course/its-a-wonderful-life-if-you-receive-the-right-meds-a-discussion-of-pharmaceutical-negligence ). Mr. Brown’s ... rating from the nationwide audience. The course focused on the challenges ...
(Date:7/31/2015)... ... ... As part of their company mission, Dallas pet sitting company Park ... to the longevity of their business. It is for that reason they are ... (NAPPS) annual Presents 4 Pets supply drive. Presents 4 Pets is a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Transfinder, a software company based in Schenectady, ... up 16 percent year-over-year for the first six months ended June 30, 2015 compared ... Transfinder to beat last year’s record-revenue mark of $10.4 million. , “We know what ...
(Date:7/31/2015)... Topsfield, MA (PRWEB) , ... July 31, 2015 ... ... of this year’s “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, ... Connecticut, November 5 and 6. The event attracts over 250 “C”-level executives, ...
Breaking Medicine News(10 mins):Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3
... Registration for Nov 14-15 Conference - including ... http://www.CHADD.org , WASHINGTON, Oct. 23 ... Adults with,Attention-Deficit/Hyperactivity Disorder, will host its 20th ... Anaheim, CA. The,three-day CHADD conference offers an ...
... Intent.com Features the Best-of-Web Content, Blogs and a Supportive Online ... ... Wellness, SANTA MONICA, Calif., Oct. 23 Whether you want ... or help bring,about world peace, a new site, Intent.com, can help you ...
... (NYSE Alternext US: FIT), a leading provider of ... it,will report financial results for the third quarter ... after the market closes. The company will also,hold ... the results. Participating,in the call will be Dr. ...
... USC/Norris Comprehensive Cancer,Center announced that Judy and ... to the USC/Norris Comprehensive Cancer Center, Keck School ... Judy and Larry Freeman Cancer,Day Hospital, an outpatient ... USC/Norris Cancer Hospital. Larry Freeman is the founder ...
... 23 Morris Animal Foundation (MAF) provides,a unique ... via its,animal health study sponsorships. In 2009, MAF ... both individuals and groups, are invited to,sponsor or ... gift of $3,000 or,more per study. The complete ...
... LifeSync Corporation,announced it has entered into a ... 12,000 members in 20 states, for the sale ... products., Shelley Hartman, President of LifeSync Corp., ... with MAGNET. MAGNET is a major supply chain,leader ...
Cached Medicine News:Health News:CHADD to Host International Conference on AD/HD in Anaheim, CA; Olympian Bruce Jenner to Keynote 2Health News:Intent.com Launches Premier Wellness Site & Social Network 2Health News:HealthFitness Corporation to Report 2008 Third Quarter Financial Results 2Health News:USC Cancer Center Announces Contribution By Larry and Judy Freeman 2Health News:Unique Way to Help Your Favorite Animal - Morris Animal Foundation's 2009 Sponsorship Guide Provides Nearly 200 Options 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: